News25/Ratings9
News · 26 weeks40-67%
2025-10-262026-04-19
Mix2690d
- Insider11(42%)
- SEC Filings8(31%)
- Other6(23%)
- Earnings1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Bhatt Elizabeth4 - Septerna, Inc. (0001984086) (Issuer)
- SECSepterna Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Septerna, Inc. (0001984086) (Filer)
- PRSepterna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of HypoparathyroidismTrial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in Late 2026 or Early 2027 SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical trial of SEP-479, its potent oral small molecule PTH1R agonist being developed for the treatment of patients with hypoparathyroidism. The Phase 1 clinical trial is a single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial
- SECSEC Form S-3ASR filed by Septerna Inc.S-3ASR - Septerna, Inc. (0001984086) (Filer)
- SECSEC Form S-8 filed by Septerna Inc.S-8 - Septerna, Inc. (0001984086) (Filer)
- SECSEC Form 10-K filed by Septerna Inc.10-K - Septerna, Inc. (0001984086) (Filer)
- SECSepterna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Septerna, Inc. (0001984086) (Filer)
- PRSepterna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial ResultsCompelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R Agonist) Toward Phase 1 Initiation in First Half of 2026 Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the fourth quarter and full year ended December 31, 2025.
- INSIDERChief People Officer Shaikhly Samira exercised 70,453 shares at a strike of $1.84 and sold $1,979,838 worth of shares (70,453 units at $28.10) (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
- SECSepterna Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Septerna, Inc. (0001984086) (Filer)
- PRSepterna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development StrategySEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports Once-Daily Oral Dosing Phase 2 Development Planned to Begin with Chronic Spontaneous Urticaria in the Second Half of 2026 Company to Host Conference Call and Webcast on Monday, March 2, 2026, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., March 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering oral small molecule GPCR-targeted medicines,
- PRSepterna to Present at TD Cowen 46th Annual Health Care ConferenceSOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 p.m. ET in Boston. A live webcast of the presentation will be available in the investors section of the company's website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation. About SepternaSepterna, Inc. is a clinical-stage biotechnology company wit
- INSIDERPresident and COO Bhatt Elizabeth exercised 4,000 shares at a strike of $6.81 and sold $115,860 worth of shares (4,000 units at $28.97) (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Septerna Inc.SCHEDULE 13G/A - Septerna, Inc. (0001984086) (Subject)
- INSIDERSEC Form 4 filed by SVP, Drug Discovery Long Daniel D.4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by SVP, Biological Sciences Klein Uwe4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Chief People Officer Shaikhly Samira4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Labrucherie Gil M4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Kim Jae B.4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by President and COO Bhatt Elizabeth4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Finer Jeffrey4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Wilson Mark Andrew4 - Septerna, Inc. (0001984086) (Issuer)
- PRSepterna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced today that on February 6, 2026, the company's Board of Directors granted an inducement award to Mark A. Wilson, Septerna's Chief Legal Officer, consisting of a non-qualified stock option to purchase 165,000 shares of common stock under the Company's 2026 Inducement Plan. The award was granted as an inducement material to Mr. Wilson's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $25.41 per share, equal to Septerna's clo